Ganirelix

Ganirelix Uses, Dosage, Side Effects, Food Interaction and all others data.

Ganirelix is an injectable competitive gonadotropin-releasing hormone antagonist (GnRH antagonist). It is utilized frequently in assisted reproduction therapy to control the occurrence of ovulation. The drug exerts its effects by inhibiting the action of GnRH in the pituitary gland, leading to fast suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Ganirelix is used in fertility treatment to prevent premature ovulation that could result in the harvesting of eggs that are too immature to be used in procedures such as in vitro fertilization. Ganirelix is marketed by Merck & Co., Inc. as Orgalutran®.

Trade Name Ganirelix
Availability Prescription only
Generic Ganirelix
Ganirelix Other Names Ganirelix
Related Drugs Sprintec, Estarylla, ethinyl estradiol / norethindrone, Ortho Tri-Cyclen, Tri-Sprintec
Weight 250mcg/0.5ml,
Type Subcutaneous Solution, Subcutaneous
Formula C80H113ClN18O13
Weight Average: 1570.35
Monoisotopic: 1568.8423035
Protein binding

81.9%.

Groups Approved
Therapeutic Class
Manufacturer
Available Country United States
Last Updated: September 19, 2023 at 7:00 am
Ganirelix
Ganirelix

Uses

Ganirelix is a GnRH antagonist used in assisted reproduction in women undergoing controlled ovarian hyperstimulation to control ovulation by inhibiting the premature LH surges.

For the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation.

Ganirelix is also used to associated treatment for these conditions: Controlled ovarian hyperstimulation therapy

How Ganirelix works

Ganirelix acts by competitively blocking the GnRH receptors on the pituitary gonadotroph and subsequent transduction pathway. It induces a rapid, reversible suppression of gonadotropin secretion. The suppression of pituitary LH secretion by ganirelix is more pronounced than that of FSH. An initial release of endogenous gonadotropins has not been detected with ganirelix, which is consistent with an antagonist effect. Upon discontinuation of ganirelix, pituitary LH and FSH levels are fully recovered within 48 hours.

Food Interaction

No interactions found.

Ganirelix Drug Interaction

Moderate: hcg

Volume of Distribution

The mean (SD) volume of distribution of Ganirelix in healthy females following intravenous administration of a single 250 mg dose is 43.7 (11.4) L.

Elimination Route

Ganirelix is rapidly absorbed following subcutaneous injection with maximum serum concentrations reached approximately one hour after dosing.

Half Life

16.2 hours.

Clearance

Single dose: 2.4L/hour Multiple dose: 3.3L/hour

Elimination Route

On average, 97.2% of the total radiolabeled ganirelix dose is recovered in the feces and urine (75.1% and 22.1%, respectively) over 288 h following intravenous single dose administration of 1 mg [14 75 C]-ganirelix acetate. Urinary excretion is virtually complete in 24 h, whereas fecal excretion starts to plateau 192 h after dosing.

Innovators Monograph

You find simplified version here Ganirelix

*** Taking medicines without doctor's advice can cause long-term problems.
Share